Clinical trials: Head and Neck Cancer Patients
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8
Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors
This phase I trial studies the best dose of sonidegib when given together with pembrolizumab and to see how well they work in treating patients with solid tumor that has spread to other places in the body (advanced).
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
- Trial name
- NCT04007744
- Testing
- Pembrolizumab, Sonidegib
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Mayo Clinic
Nasopharyngeal Carcinoma by AJCC V8 Stage
Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
The goal of this study is to learn the efficacy and safety of nimotuzumab combined with toripalimab and gemcitabine/cisplatin regimen treatment recurrent/distant-metastasis nasopharyngeal carcinoma.
- Trial name
- NCT06509009
- Testing
- Nimotuzumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Advanced Breast Cancer, Advanced Carcinomas With Squamous Cell Histology
A Phase I Study of BKM120 in Adult Chinese Patients With Advanced Solid Tumors
Dose escalation study with a dose expansion phase, to evaluate safety, tolerability, pharmacokinetics and preliminary efficacy of two dose levels of BKM120 when administered orally.
- Trial name
- NCT01626209
- Testing
- BKM120
- Where
- 3 sites in China
- Volunteers
- 32 people
- Sponsor
- Novartis Pharmaceuticals
Pancreatic Cancer, Melanoma
Immunotherapy Study of Evofosfamide in Combination With Ipilimumab
An immunotherapy study combining ipilimumab and evofosfamide for the treatment of patients with confirmed metastatic or locally advanced prostate cancer, metastatic pancreatic cancer, melanoma or human papillomavirus (HPV)…
- Conditions
- Pancreatic Cancer, Melanoma, Squamous Cell Carcinoma of the Head and Neck, Prostate Cancer
- Trial name
- NCT03098160
- Testing
- Evofosfamide, Ipilimumab
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- Threshold Pharmaceuticals
Carcinoma of Unknown Primary, Head and Neck Cancer
PET Scans and CT Scans in Patients With Locally Advanced Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy
RATIONALE: Imaging procedures, such as PET scan and CT scan, may help doctors predict a patient's response to treatment and plan the best treatment.
- Trial name
- NCT00388024
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Wake Forest University Health Sciences
Esophagus Cancer
The Efficacy and Safety of Caffeic Acid for Esophageal Cancer
Caffeic acid can target inhibit GASC1 (gene amplified in squamous cell carcinoma 1, also known as KDM4C and JMJD2C) expression and GASC1 is confirmed to be a new oncogene in several cancers including esophageal cancer.
- Trial name
- CAEC (NCT03070262)
- Testing
- CA
- Where
- China
- Volunteers
- 300 people
- Sponsor
- The First Affiliated Hospital of Henan University of Science and Technology
Nasopharyngeal Cancer, Prostate Cancer
Discovery of Biomarkers for Intrinsic Radiation Sensitivity in Cancer Patients
Patients with cancers that are sensitive to radiotherapy treatment and/or patients who have experienced severe acute/ late side effects to radiotherapy will be recruited to the study.
- Conditions
- Nasopharyngeal Cancer, Prostate Cancer, Other Cancer
- Trial name
- NCT04340024
- Where
- Singapore
- Volunteers
- 5,000 people
- Sponsor
- National Cancer Centre, Singapore
Symbiotic, Cancer Colorectal
Effect of the Use of Symbiotics in Patients With Colon Cancer
Due to the high incidence, cancer and the concomitant presence of malnutrition are currently a worldwide public health problem. The loss of weight and body tissues is a common condition in cancer patients with lesions of the…
- Conditions
- Symbiotic, Cancer Colorectal, Cancer Head Neck, Intestinal Dysbiosis
- Trial name
- NCT04874883
- Testing
- Simbyotic, Control Group
- Where
- 2 sites in Brazil
- Volunteers
- 42 people
- Sponsor
- Federal University of Minas Gerais
Lip and Oral Cavity Squamous Cell Carcinoma, Oral Cavity Verrucous Carcinoma
Direct Visual Fluorescence in Finding Oral Cancer in High-Risk Patients and Patients Undergoing Routine Dental Care
This clinical trial studies direct visual fluorescence in finding oral cancer in high-risk patients and patients undergoing routine dental care.
- Conditions
- Lip and Oral Cavity Squamous Cell Carcinoma, Oral Cavity Verrucous Carcinoma, Stage 0 Lip and Oral Cavity Cancer, Tongue Cancer
- Trial name
- NCT01816841
- Testing
- fluorescence imaging, biopsy, examination
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Colorectal Cancer, Esophageal Cancer
Monoclonal Antibody ABX-EGF in Treating Patients With Renal (Kidney), Prostate, Pancreatic, Non-Small Cell Lung, Colon or Rectal, Esophageal, or Gastroesophageal Junction Cancer
RATIONALE: Monoclonal antibodies such as ABX-EGF can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Colorectal Cancer, Esophageal Cancer, Kidney Cancer, Lung Cancer
- Trial name
- NCT00004879
- Testing
- panitumumab
- Where
- 2 sites in United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Esophageal Squamous Cell Carcinoma, Chemoradiotherapy
Whole-course Immunonutrition Combined With Chemoradiotherapy±ICIs for Local Advanced Patients With Inoperable Esophageal Squamous Cell Carcinoma
Chemoradiotherapy has been a standard modality for inoperable locally advance esophageal carcinoma. The goal of this randomized control study is to compare the feasibility, and survival benefits of whole-course immunonutrition…
- Conditions
- Esophageal Squamous Cell Carcinoma, Chemoradiotherapy, Immunonutrition, Inoperable
- Trial name
- NCT05833594
- Testing
- Whole-course Immunonutrition Combined With Chemoradiotherapy±ICIs
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Anhui Provincial Hospital
Neoplasm
Modern Hybrid Imaging in Patients With OSCC
Prospective diagnostic study to determine the diagnostic accuracy of preoperative 18F--fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) in detecting local tumor extent, cervical lymph node…
- Trial name
- PETOSCC (NCT04280159)
- Where
- Germany
- Volunteers
- 265 people
- Sponsor
- Wuerzburg University Hospital
Head and Neck Cancer
A Study in Head and Neck Cancer
This study will begin with a 30 participant lead-in part: these 30 participants will receive cetuximab manufactured by ImClone on a weekly basis in combination with other chemotherapy drugs [cisplatin or carboplatin plus…
- Trial name
- NCT01081041
- Testing
- Cetuximab, Cisplatin, Carboplatin
- Where
- 26 sites in United States, Canada and 1 more
- Volunteers
- 187 people
- Sponsor
- Eli Lilly and Company
Locally Advanced Esophageal Squamous Cell Carcinoma
Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007)
Although definitive chemoradiotherapy (CRT) is the standard treatment option for unresectable locally advanced esophageal cancer, elderly patients tolerate intravenous concurrent CRT less well with age and comorbidities.
- Trial name
- EC-CRT-007 (NCT06187597)
- Testing
- S-1, Toripalimab, Intensity-modulated radiotherapy
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Sun Yat-sen University
Head and Neck Squamous Cell Carcinoma, Anal Squamous Cell Carcinoma
Oral Rigosertib for Squamous Cell Carcinoma
The primary objective of this study is to determine if tumors in patients with papillomavirus (HPV) positive or negative squamous cell carcinoma (SCC) that no longer responds to standard therapy will decrease in size following…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Anal Squamous Cell Carcinoma, Lung Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma
- Trial name
- NCT01807546
- Testing
- rigosertib
- Where
- 13 sites in United States
- Volunteers
- 64 people
- Sponsor
- Traws Pharma, Inc.
Erythroplakia, Oral Leukoplakia
Metformin for the Prevention of Oral Cancer in Patients With Oral Leukoplakia or Erythroplakia
This phase IIb trial tests whether metformin works in preventing oral cancer in patients with oral leukoplakia (white patches) or erythroplakia (red patches). Metformin is in a class of drugs called biguanides.
- Trial name
- NCT05237960
- Testing
- Biopsy, Biospecimen Collection, Extended Release Metformin Hydrochloride
- Where
- 10 sites in United States, Canada
- Volunteers
- 34 people
- Sponsor
- University of Arizona
Mucositis, Solid Tumors
Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer
The purpose of this research study is to test the safety and effectiveness of palifermin to determine if weekly doses can be safely administered to reduce the incidence (occurrence of), duration (length of time) and severity…
- Conditions
- Mucositis, Solid Tumors, Stomatitis, Head and Neck Cancer
- Trial name
- NCT00101582
- Testing
- palifermin, cisplatin chemotherapy, Radiotherapy
- Volunteers
- 188 people
- Sponsor
- Swedish Orphan Biovitrum
Neoplasms, Squamous Cell
IRESSA™ (Gefitinib) With Cisplatin Plus Radiotherapy for the Treatment of Previously Untreated Unresected Late Stage III/IV Non-Metastatic Head and Neck Squamous Cell Carcinoma
The primary purpose of this study is to assess the effectiveness of ZD1839 250 mg and 500 mg when given either concomitantly or as maintenance to a standard therapy of radiotherapy (X-rays) plus chemotherapy (cisplatin) in terms…
- Trial name
- NCT00229723
- Testing
- gefitinib (Iressa), cisplatin, radiotherapy
- Where
- 25 sites in United States, Belgium and 6 more
- Volunteers
- 224 people
- Sponsor
- AstraZeneca
Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
This phase II trial tests the addition of BMS-986016 (relatlimab) to the usual immunotherapy after initial treatment for nasopharyngeal cancer that has come back after a period of improvement (recurrent) or that has spread from…
- Conditions
- Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8
- Trial name
- NCT06029270
- Testing
- Biospecimen Collection, Bone Scan, Carboplatin
- Where
- 95 sites in United States, Australia and 3 more
- Volunteers
- 156 people
- Sponsor
- National Cancer Institute (NCI)
Esophageal Squamous Cell Carcinoma
Chemoradiation With or Without Nimotuzumab in Treating Esophageal Cancer Patients Who Suffer With Recurrence in Regional Lymph Nodes After Esophagectomy
A randomized phase II tials to study whether it's benefit of adding Nimotuzumab to chemoradiation for patients with esophageal squamous cell carcinoma after radical esophagectomy who suffer with locoregional lymph nodes…
- Trial name
- Nimotuzumab (NCT01402180)
- Testing
- Nimotuzumab, Radiation therapy, chemotherapy
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Fudan University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.